Skip to main content

Table 1 Baseline characteristics of study participants

From: High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial

Characteristic

Active HFCWO

(n = 25)

Sham HFCWO

(n = 27)

p-value

Diagnosis, n (%)

Acute asthma

15 (60)

16 (59)

> 0.99

 

Acute COPD

9 (36)

10 (37)

 
 

Acute asthma and COPD

1 (4)

1 (4)

 

Age, years

46.5 [38.6, 52.8]

50.4 [43.9, 60.7]

0.28

BMI, kg/m 2

27.0 [23.7, 33.0]

29.7 [23.7, 38.0]

0.43

Post-BD FEV 1 % predicted

45 [26, 58]

n = 23

40 [33, 55]

n = 25

0.75

Post-BD FEV 1 /FVC, %

61 [49, 66]

n = 23

55 [49, 66]

n = 25

0.55

Hospitalizations past year (excluding current)

1 [0, 3]

n = 21

1 [0, 4]

n = 21

0.98

Emergency room visits past year

2 [0, 4]

4 [0, 5]

n = 25

0.50

Corticosteroid courses past year

2 [0, 4]

n = 24

2 [0, 5]

n = 25

0.58

  1. The median [interquartile range] is reported, unless otherwise stated. The number (n) of participants with data is included in the table, if n is less than the number of participants assigned to each treatment group. Missing data were due to difficulty in performing some tests in acutely ill patients (e.g., post-BD spirometry) or non-response (e.g., problems with patient recall). HFCWO = high frequency chest wall oscillation, BMI = body mass index, Post-BD FEV1= post-bronchodilator forced expiratory volume in 1 second, Post-BD FEV1/FVC = post-bronchodilator forced expiratory volume in once second/forced vital capacity.